Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
Delcath Systems (DCTH) Stock Price & Analysis
582 Followers
DCTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $7.99
Previous Close$5.6
Volume146.95K
Average Volume (3M)212.75K
Market Cap
$137.55M
Enterprise Value$115.28M
Total Cash (Recent Filing)$32.45M
Total Debt (Recent Filing)$10.19M
Price to Earnings (P/E)-1.9
Beta0.56
Next Earnings
May 07, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding24,562,692
10 Day Avg. Volume249,452
30 Day Avg. Volume212,746
Standard Deviation0.22
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)8.72
Price to Sales (P/S)64.83
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue55.83
Enterprise Value/Gross Profit80.62
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$19.00Price Target Upside261.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Delcath Systems News
PremiumPre-Earnings
Is DCTH a Buy, Before Earnings?
PremiumCompany Announcements
Delcath Systems Welcomes New COO Martha S. Rook
Bulls Say, Bears Say
Bulls Say
Analyst SentimentAnalysts are optimistic about Delcath Systems, with a 'Buy' recommendation and a $16 price target based on the strong sales potential and market opportunity for Hepzato.
Growth And AdoptionWith over 20 sites interested in Hepzato and expectations of more sites offering the treatment, there's a clear trajectory for increased usage and market penetration.
Product Approval And Market PotentialThe FDA approval of the Hepzato Kit for metastatic ocular melanoma marks a significant step forward, potentially disrupting the market with a new treatment option.
Bears Say
Commercial Roll-out ImpactThe REMS program may initially limit the number of treatment sites able to offer Hepzato, affecting the speed of its commercial roll-out.
Operational HurdlesThe REMS Program requires extensive training and proctoring, which may initially limit the number of sites able to perform commercial cases immediately after launch.
Regulatory ChallengesThe REMS program may initially limit the number of sites able to perform commercial cases immediately after launch.
---
Ownership Overview
30.27% Insiders
2.64% Mutual Funds
13.89% Other Institutional Investors
53.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $2.25 and its highest was $7.99 in the past 12 months.
What is Delcath Systems’s market cap?
Currently, no data Available
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is May 07, 2024 which is in 12 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Mar 26, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.539 by $0.059.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -$0.47.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 24,562,693 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.539. Following the earnings report the stock price went down -1.073%.
Which hedge fund is a major shareholder of Delcath Systems?
Among the largest hedge funds holding Delcath Systems’s share is Deerfield Management Company, LP. It holds Delcath Systems’s shares valued at N/A.
---
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (261.22% Upside)
$19.00 (261.22% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 486.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.62%
12-Months-Change
Fundamentals
Return on Equity
-961.44%
Trailing 12-Months
Asset Growth
116.17%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.
---
DCTH Earnings Call
Q4 2024
0:00 / 0:00
---
DCTH Stock 12 Months Forecast
Average Price Target
$19.00
▲(261.22% Upside)
Technical Analysis
Best Analysts Covering DCTH
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
-11.09%
reiterated a buy rating last month
Copying Marie Thibault's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -11.09% per trade.
---